← Compound index
COMPOUND RECORD / TAXOREST

TaxorestТаксорест

A peptide mixture from the bronchial lining of young cattle or pigs, studied in a Russian respiratory report.

Source linked

What the studies found

Comparison in people · 2011

Taxorest: clinical report on a tissue-derived preparation

Forced expiratory vital capacity
3,940.5 ± 123.6 mL with Taxorest versus 3,225.6 ± 148.2 mL with conventional care. Shared baseline 2,767.8 ± 134.7 mL.
Vital capacity
4,220.7 ± 243.1 mL with Taxorest versus 3,876.5 ± 215.4 mL with conventional care. Shared baseline 3,654.1 ± 231.9 mL.
Total lung capacity
5,246.1 ± 223.6 versus 5,075.4 ± 211.6 mL. The table gives no significance mark for total lung capacity.

Forced expiratory vital capacity was 3,940.5 mL with adjunctive Taxorest and 3,225.6 mL with conventional care. Significance was marked against the shared baseline.

Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology

Study notes · methods, sources and limitations

Participants or model 52 smokers with bronchitis: 31 treated, 21 controls.

Design 52 smokers with chronic bronchitis in remission, 31 receiving adjunctive Taxorest and 21 conventional therapy alone. The studied oral schedule was one 10 mg capsule with meals twice daily (20 mg/day) for 30 days.

Important limitations

  • Allocation and blinding are not established. Within-group improvement cannot establish superiority or protection against smoking-related disease. Commercially reproduced institute report; independent peer review and independent replication are not established by this document. Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
  • The table marks changes against the shared baseline. It gives no between-group statistical test.

Institute clinical report (commercial reproduction); 2011 study/report date, not website publication date · Institute report — commercial reproduction

Original source or citation ↗

Study results and tables ↗
01 / OVERVIEW

About Taxorest

Identity / background source ↗

Research background

Taxorest is a respiratory tissue peptide preparation. A 52-person Medical Center report measured pulmonary function in smokers with bronchitis.

Compound class
Tissue-derived peptide preparation
Research collection
Peptide bioregulation · editorial grouping
Institutions in linked studies
Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

52 smokers with bronchitis: 31 treated, 21 controls.

Study methods

Small comparative institute report; allocation, blinding and outcome interpretation require caution

Independent replication

Independent replication not established in this collection

Source access

Report reproduction linked; source language and review scope shown per record

Safety evidence

Short-term reports do not establish long-term safety or equivalence to current products

Open a topic for the evidence assessment.

More findings, background and history

What remains unclear

The original report and protocol would clarify group sizes, background treatment and translation. Independent replication and equivalence to current products remain uncertain.

Human reports are linked; their presence does not establish effectiveness. Several publications can describe the same participants.

Browse original study records ↗

Explore the expanded peptide research collection and unresolved source trails ↗

View this preparation in the Khavinson evidence map ↗

03 / SOURCE RECORDS

Findings by study

Tissue-preparation reports: comparisons, source limits and remaining gaps ↗

Explore related research ↗

Comparison in people · 2011

Taxorest: clinical report on a tissue-derived preparation

Forced expiratory vital capacity was 3,940.5 mL with adjunctive Taxorest and 3,225.6 mL with conventional care. Significance was marked against the shared baseline.

Forced expiratory vital capacity · 3,940.5 ± 123.6 mL with Taxorest versus 3,225.6 ± 148.2 mL with conventional care. Shared baseline 2,767.8 ± 134.7 mL.

Study notes and original source
2011Human comparative studyFull text available

Taxorest: clinical report on a tissue-derived preparation

Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology

Tissue-derived mixture / named preparation · Institute report — commercial reproduction

St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute clinical report (commercial reproduction); 2011 study/report date, not website publication date

Forced expiratory vital capacity was 3,940.5 mL with adjunctive Taxorest and 3,225.6 mL with conventional care. Significance was marked against the shared baseline.

Results and tables

Reported findings and study design

52 smokers with chronic bronchitis in remission, 31 receiving adjunctive Taxorest and 21 conventional therapy alone. The studied oral schedule was one 10 mg capsule with meals twice daily (20 mg/day) for 30 days.

Population or model 52 smokers with bronchitis: 31 treated, 21 controls.

Results · Russian Medical Center report, PDF pages 80–81, Table 1
MeasureResultComparison, timing and statistics
Forced expiratory vital capacity3,940.5 ± 123.6 mL with Taxorest versus 3,225.6 ± 148.2 mL with conventional care. Shared baseline 2,767.8 ± 134.7 mL.
Vital capacity4,220.7 ± 243.1 mL with Taxorest versus 3,876.5 ± 215.4 mL with conventional care. Shared baseline 3,654.1 ± 231.9 mL.
Total lung capacity5,246.1 ± 223.6 versus 5,075.4 ± 211.6 mL. The table gives no significance mark for total lung capacity.

The table marks changes against the shared baseline. It gives no between-group statistical test.

Source for these results ↗ · Reviewed 2026-11-16

Population / setting
52 smokers with bronchitis: 31 treated, 21 controls.
Source reviewed
Russian Medical Center report, PDF pages 80–81, methods and spirometry table.
Study limitations
  • Allocation and blinding are not established. Within-group improvement cannot establish superiority or protection against smoking-related disease.
  • Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
  • Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.

Reviewed 2026-11-16.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗